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Executive summary 
BACKGROUND: Non-bismuth quadruple sequential therapy (SEQ) has been suggested as a new first-
line treatment option to replace the standard triple therapy (STT), in which eradication rates have 
declined to disappointing levels.  
AIM: To conduct a meta-analysis of studies comparing SEQ vs. STT for H. pylori eradication.  
METHODS: Selection of studies: randomized controlled trials (RCTs) comparing SEQ (10 days) and STT 
(at least 7 days) for the eradication of H. pylori. Search strategy: bibliographical searches in 
electronic databases and manual search of abstracts from Congresses were conducted up to May 
2013. Data synthesis: intention-to-treat (ITT) eradication rate.  
RESULTS: 30 RCTs were included with a total of 8,878 patients (4,173 in the SEQ and 4,705 in the 
STT). The overall analysis showed that SEQ was significantly more effective than STT (84% vs. 74% in 
the ITT analysis; OR= 2.06; [95%CI= 1.59-2.66]; p<0.001). Results were highly heterogeneous 
(I2=78%) and 10 studies were unable to demonstrate differences between therapies. Subgroup 
analyses suggested that patients with clarithromycin resistance and/or taking esomeprazole-
rabeprazole could benefit more from SEQ. However there were no differences when STT lasted 14 
days. Although, overall, mean eradication rate with SEQ was over 80%, a tendency towards lower 
efficacy with this regimen was observed in the more recent studies [weighted linear regression per 
year -0.02 (-2% per year) in SEQ vs. -0.005 (-0.5% per year) in STT], and in studies performed outside 
Italy (OR 1.48 vs. 4.09). 
CONCLUSION: The meta-analysis demonstrated that SEQ is more effective than STT lasting less than 
14 days. Nevertheless, the apparent advantage of sequential treatment seems to be decreasing 
overtime; therefore further and continuous assessment is needed before a generalized change in all 
settings is recommended for first line H. pylori treatment. 
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Resumen 
ANTECEDENTES: La terapia secuencial se ha sugerido como primera línea de tratamiento en 
sustitución de la triple terapia clásica, cuya tasa de erradicación ha disminuido hasta alcanzar valores 
inaceptables. 
OBJETIVO: Realizar un metaanálisis de los estudios que comparan la terapia secuencial frente a la 
triple terapia clásica para la erradicación de H. pylori. 
MÉTODOS: Selección de estudios: Ensayos clínicos aleatorizados que comparan la terapia secuencial 
(10 días) y la triple terapia clásica (al menos 7 días) para la erradicación de H. pylori. Estrategia de 
búsqueda: electrónica y manual hasta Mayo de 2013. Síntesis de los datos: tasa de erradicación por 
intención de tratar. 
RESULTADOS: Se han incluido finalmente 30 ensayos clínicos aleatorizados con un total de 8.878 
pacientes tratados (4.173 con la terapia secuencial y 4.705 con la triple terapia clásica). El análisis en 
su conjunto mostró que la terapia secuencial era significativamente más efectiva que la triple terapia 
clásica (84% vs. 74% en el análisis por intención de tratar; OR=2,06; [I.C.95%= 1,59-2,66]; p<0,001). 
Los resultados fueron muy heterogéneos (I2=78%), y 10 estudios no mostraron diferencias 
significativas entre ambas terapias. Los subanálisis sugieren que en pacientes con cepas resistentes a 
claritromicina y/o tomando esomeprazol-rabeprazol se obtiene un aún mayor beneficio con la 
terapia secuencial. No se encontraron diferencias al comparar la terapia secuencial frente a pautas 
triples de 14 días. Aunque, globalmente, la tasa media de erradicación superó el 80%, se comprobó 
una tendencia a una menor eficacia con la terapia secuencial en los estudios más recientes 
[regresión lineal ponderada -0,02 (-2% por año) en la terapia secuencial vs. -0,005 (-0,5% por año) en 
la triple terapia clásica] y en los realizados fuera de Italia (OR 1,48 vs. 4,09). 
CONCLUSIÓN: El presente metaanálisis confirma que la terapia secuencial es más efectiva que la 
triple terapia clásica con duración inferior a 14 días.  No obstante, la ventaja del tratamiento 
secuencial sobre el estándar parece ir disminuyendo con el tiempo, por lo que se debería realizar un 
análisis exhaustivo y continuado antes de recomendar un cambio generalizado en la elección del 
tratamiento erradicador de H. pylori de primera línea. 
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1. Background 
1.1. Description of the condition 
Helicobacter pylori (H. pylori) infects more than 50% of the adult population globally[1] and is known 
to be associated with a wide range of upper gastrointestinal diseases including gastritis, peptic ulcer 
disease (PUD) and gastric cancer. The latest Maastricht IV Consensus 2[ ] has strongly recommended H. 
pylori eradication for patients with PUD, mucosa-associated lymphoid tissue (MALT) lymphoma and 
atrophic gastritis, post-gastric cancer resection, in patients who are first-degree relatives of gastric 
cancer patients and in patients with preference after consultation with physicians. It is also 
suggested that H. pylori eradication is appropriate for infected patients investigated for non-ulcer 
dyspepsia (NUD). Treatment of H. pylori may also prevent PUD, bleeding or both in naïve users of 
non-steroidal anti-inflammatory drugs (NSAIDs). 2[ ]
1.2. Description of the intervention 
  
Since 1997, a worldwide panel of experts, the European Helicobacter Study Group (EHSG) has 
recommended in its consensus conferences a triple therapy comprising a proton-pump inhibitor 
(PPI) plus two antibiotics used twice daily as first-line H. pylori eradication regimen.[2-5] Commonly, 
clarithromycin is used together with amoxicillin or nitroimidazole (metronidazole or tinidazole). 5[ , 6]
However, sequential therapy (SEQ), based on a proton-pump inhibitor (PPI) plus amoxicillin twice 
daily for the first five days followed by PPI plus clarithromycin together with nitroimidazole twice 
daily for the following five days, has been suggested as a new treatment to replace the standard 
triple therapy (STT).
 
[7, 8]
1.3. How the intervention might work 
 
The efficacy of STT is inversely related to the bacterial load and higher eradication rates are achieved 
in those with a low bacterial density in the stomach.[9, 10] It has therefore been suggested that the 
short initial dual therapy used in SEQ with amoxicillin lowers the bacterial load in the stomach in 
order to improve the efficacy of the immediately subsequent short course of triple therapy. 11[ , 12] In 
other words, it acts as an induction phase that may amplify the efficacy. The first five days of 
amoxicillin and PPI thus results in a marked reduction of H. pylori and even eradication in at least 
50% of patients. 11[ , 13] The second stage of the regimen (clarithromycin and tinidazole) acts to 
eradicate a rather small residual population of viable organisms. 13[ ] 
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Moreover, it has been suggested that the initial use of amoxicillin may offer another essential 
advantage in the eradication of H. pylori.[12] It has been found that regimens containing amoxicillin 
prevent the selection of secondary clarithromycin resistance. 14[ ]
The sequential administration of antibiotics is not generally recommended because of the fear of 
promoting drug resistance.
 The most accepted candidate theory 
suggests that SEQ might therefore improve eradication rates as the initial phase of treatment with 
amoxicillin weakens bacterial cell walls, preventing the development of drug efflux channels 
involved in the reduction of clarithromycin and other drug concentrations inside the bacteria, 
although this has not yet been demonstrated. This may allow higher concentrations of antibiotics in 
the cytoplasm during the second phase of treatment that would facilitate the binding of 
clarithromycin to the ribosomes. 
[15] However, the initial dual phase of the SEQ uses a drug (amoxicillin) 
that rarely results in resistance, such that the outcomes should be either cure of the infection or a 
marked reduction in bacterial load, making the presence of a pre-existing small population of 
resistant organisms less likely. 16[ ]
1.4. Why it is important to do this review 
 
STT is the most commonly used treatment in clinical practice. However, a critical fall in the H. pylori 
eradication rate following this therapy has been observed since the discovery of H. pylori.[15] Even in 
areas where this decrease has not been demonstrated the efficacy of the STT offers suboptimal 
results. 17[ ]
Two recent double-blind, US multicentre studies both found disappointingly low eradication rates 
with STT (77%).
  
[18, 19] Two meta-analyses including both together more than 53,000 patients have 
shown that the ITT cure rate is below 80%. 20[ , 21] Therefore, the general recommendation of STT as 
first line treatment has been questioned, even considering unethical its use as comparator in clinical 
trials. The use of alternative therapy has been recommended in its place. 22[ ]
The sequential regimen is a novel, promising therapeutic approach but eradication efficacy must be 
confirmed now that the resistance rate for clarithromycin has increased.
 
[23, 24] Almost all studies 
using the sequential regimen published during 2008, 2009 and 2010 had lower than 90% eradication 
rates and in some cases lower than 80% figures were reported. 25[ , 26]
Moreover, the most commonly used SEQ uses tinidazole, whilst in some studies metronidazole has 
been used. A recent review on SEQ
  
[27] showed that the eradication rate achieved with 
metronidazole-based regimens was significantly lower than that achieved with a tinidazole-based 
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regimen. Indeed, tinidazole has a markedly longer half-life compared to metronidazole and this 
could be cause for concern for successful H. pylori therapy.  
It is also important to mention that most of the studies considered in the previous pooled analyses 
and meta-analyses were performed in Italy.[27-29] Some of the more recent studies, including other 
regions, have not demonstrated a beneficial effect of SEQ when compared with STT but have instead 
shown equivalent eradication rates. 30[ , 31]
Previous meta-analyses have compared STT with SEQ.
 All these issues require an update of previous meta-
analyses and the sub-analysis of these factors in order to evaluate the current benefit reached with 
SEQ over STT, and to measure those variables that may affect the eradication rates.  
[28-30]
This systematic review was developed from an on-going Cochrane Review of all H. pylori eradication 
therapies.
 In our preliminary search, we identified 
several randomized controlled trials (RCTs) which were not included in the previous meta-analyses. 
We therefore conducted a systematic review of RCTs comparing SEQ versus STT for H. pylori 
eradication, using more databases, optimized search strategies and applying the rigorous techniques 
recommended by the Cochrane Collaboration and including later published studies.  
[32] 
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2. Objectives 
2.1. Primary objective 
To conduct a meta-analysis of randomized controlled trials comparing the efficacy of a sequential 
regimen vs. standard triple therapy for the eradication of H. pylori infection. 
2.2. Secondary objective 
To compare the incidence of adverse effects associated with both standard triple and sequential H. 
pylori eradication therapies. 
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3. Methods 
3.1. Criteria for considering studies for this review 
This systematic review was conducted using the manual for developing systematic reviews: The 
Cochrane Handbook for systematic reviews of Interventions.[33] Since systematic reviews are by 
nature retrospective, it is essential to document the methods to be used. A pre-defined approach 
was therefore developed as part of the protocol 34[ ] prior to knowledge of the evidence available to 
reduce the impact of review authors’ biases, promote transparency of methods and processes, and 
allow peer review of the planned methods and different stages to guide the systematic review. 35[ ]
3.2. Selection criteria 
 
The protocol outlined the study question, detailed the criteria against which studies were to be 
assessed for inclusion and described how the review process should be managed (for instance, by 
identifying the methods used, the type of information to data extract and how upcoming 
amendments were to be dealt with). The protocol defined fields such as the health problem, the 
intervention under investigation, the outcomes measures, and the study design of interest. The 
process for identifying, evaluating and summarizing the studies across the review was additionally 
described and validated by several clinical experts.  
Any modification taking place during the systematic review process was highlighted and reported 
within the corresponding phase / heading of present report. 
3.2.1. Types of studies 
Only parallel-group, randomized controlled trials (RCTs) were eligible for inclusion in the review. 
Non-randomized studies, case reports, letters, editorials, commentaries and reviews were excluded. 
 
Regarding the date of the publication, no threshold was defined. No language restrictions were 
applied during the eligibility of studies.  
3.2.2. Types of participants 
The study population included adults and children diagnosed as positive for H. pylori (with at least 
one confirmatory test) on the basis of monoclonal stood antigen test, rapid urease test (RUT), 
histology or culture of an endoscopic biopsy sample, or by a urea breath test (UBT). 
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Trials in which participants were diagnosed as H. pylori positive solely on the basis of serology or 
polymerase chain reaction (PCR), or who had previously been treated with an eradication therapy 
were excluded.  
3.2.3. Types of interventions 
Trials comparing a SEQ vs. a STT for H. pylori eradication as defined below were included. 
Additionally, studies that were not assessing an H. pylori treatment or that were focusing on other 
gastrointestinal conditions were directly excluded. 
 
Any variations in the interventions’ schedule other than the specified regarding its length or the type 
or dosage of the antibiotic used were subject to the study exclusion.  
 
3.2.3.1. Sequential therapy (SEQ) 
The 10-day SEQ was comprised of a PPI twice daily and amoxicillin 1 g twice daily for the first five 
days followed by PPI twice daily, clarithromycin 500 mg twice daily and tinidazole or metronidazole 
twice daily for the following five days.  
3.2.3.2. Standard triple therapy (STT) 
The STT consisted of a PPI twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice 
daily lasting at least seven days.  
3.2.4. Types of outcomes measures 
3.2.4.1. Primary outcomes 
Trials were included if they reported the number of patients with H. pylori eradication.  
Trials were eligible if H. pylori eradication was confirmed using RUT or histology of an endoscopic 
biopsy sample or by a UBT or a monoclonal stool antigen test, at least four weeks after completion 
of treatment.  
Assessments by serology test alone or by culture alone were not satisfactory and subject to 
exclusion. 
3.2.4.2. Secondary outcomes 
Reported incidence of AEs was also included.  
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AEs incidence was recorded as the number of patients reporting: any type of AE; any gastrointestinal 
disturbance such as nausea or vomiting; any dermatological problem; any systemic effect (fever, 
headache or dizziness); or any serious AE. 
A serious AE was assumed as the occurrence of any undesirable and important medical event such 
as for e.g. death, life- threatening situation, hospitalization, permanent damage associated with any 
medical drug. A serious AE was not to be confused with a severe AE – an intense form of AE that 
usually incapacitates individual normal life. Reported severe AEs were also collected.  
Reported treatment compliance (or adherence) rate defined as the extent to which a patient fulfilled 
with the corresponding prescribed treatment in terms of drug type, dosage and length was 
collected.  
Reported withdrawals rate recorded as the number of patients discontinuing treatment due to AEs, 
was also of interest. 
3.3. Search methods for identification of studies 
3.3.1. Electronic searches 
Bibliographical searches were performed in MEDLINE, EMBASE and CINAHL electronic databases and 
in the Cochrane Central Register of Controlled Trials (CENTRAL) through the Cochrane Library 
(Appendix: search strategy ).  
Search terms were combined to capture 2 components of the study question: the disease (H. pylori 
infection) and the intervention of interest (standard triple therapy vs. sequential therapy). Following 
combination of terms (all fields) was used: (Helicobacter OR pylori) AND sequential AND (triple OR 
“standard regimen” OR “standard therapy”). Hand-searches were adapted and performed using the 
same syntax. 
The design of the search was refined by the Trials Search Coordinator at the Cochrane Upper 
Gastrointestinal and Pancreatic Diseases Review Group of the Cochrane Collaboration.  
The first electronic search was run up to February 2011 and 4,670 citations (MEDLINE= 1,365; 
EMBASE= 3,504; CENTRAL= 1,569; CINAHL= 362) were retrieved. Due to time constraints, an 
additional search was run up to May 2013 and 125 new citations were added (MEDLINE= 76, 
EMBASE= 27, CENTRAL= 30, CINAHL=30). 
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3.3.2. Searching other sources 
Additional hand-searches of websites were conducted in order to retrieve additional publications 
not captured by the electronic searches. The manual search aimed to identify abstracts of RCTs that 
might not have been published in peer-reviewed journals but only as part of conference 
proceedings, specialised journals or international congresses such as the International Workshop of 
the European Helicobacter Study Group (EHSG), the American Digestive Disease Week (DDW) and 
the United European Gastroenterology Week (UEGW).  
Each of the abstracts identified as potentially eligible was reviewed and only those meeting the 
inclusion criteria were recorded for inclusion.  
Detailed cross referencing from bibliographies of the included studies as well as from other 
systematic reviews was conducted in order to identify further relevant trials. 
3.4. Data collection and analysis 
3.4.1. Selection of studies 
Prior to the selection of studies phase, most duplicates were automatically removed when studies 
were imported to the citation manager for their management. Remaining duplicates were removed 
manually during the first screening phase. 
The selection of retrieved studies from the searches was conducted in two phases. An initial 
screening of titles and abstracts (first screening phase) against the inclusion criteria was undertaken 
to identify the potentially relevant publications. Following this step, the screening of the full paper 
(second screening phase) of the studies identified as potentially eligible for inclusion during the first 
screening phase was performed.  
In the case of abstracts or articles with insufficient detail to meet the inclusion criteria, authors were 
contacted.  
Based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
approach (http://www.prisma-statement.org), a diagram was developed in order to schematize 
previously mentioned steps used for the identification and the selection of studies.  The number of 
studies considered at each step and the reason for exclusion of each of the excluded studies was 
specified. 
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The process of both the first and second screening was carried out by two review authors (AGM and 
OPN) independently. Any discrepancies were resolved by discussion and a third review author (JPG) 
was consulted for unresolved disagreements. 
3.4.2. Data extraction and management 
A data extraction form that had been previously pre-tested was developed during the protocol 
phase to record data from the selected papers. Following fields were collected during the data 
extraction process:  
• first author’s name and year of publication;  
• country;  
• format of publication (abstract versus journal article);  
• age of the population (adult versus children);  
• medical condition (PUD or NUD or other);  
• number of patients in each treatment group;  
• name, dose and timing of antibiotic administration;  
• length of STT;  
• eradication rate per treatment regimen [intention-to-treat (ITT) and per-protocol (PP)]: if 
only the PP sample was reported, the ITT sample was calculated on the basis of the  
randomization and drop-out information; 
• definition of compliance and the compliance rate in the ITT sample;  
• details of the method of assessment of H. pylori infection both before and after treatment; 
• whether the antibiotic sensitivity and resistance was tested before and after eradication; if 
so, the primary and secondary antibiotic resistance rate;  
• incidence, type and severity of AEs; 
• study quality: generation of the treatment allocation, concealment of the treatment 
allocation at randomization, implementation of masking, completeness of follow-up and use 
of ITT analysis. 
Authors of primary studies were contacted for any missing data.  
The process of the data extraction was undertaken by two review authors (AGM and OPN) 
independently. Consensus was reached when discrepancies occurred. If consensus was not 
achieved, the opinion of a third review author (JPG) was obtained. 
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3.4.3. Assessment of risk of bias in included studies 
Four components of quality were assessed following the quality checklist recommended in the 
Cochrane Handbook for Systematic Reviews and Interventions. [33] The quality of the trials was 
assessed according to the information available in the published trials as per the risk of 
overestimating intervention effects in RCTs with inadequate methodological quality. 36[ ]
3.4.4. Generation of the treatment allocation  
 Authors 
were contacted for any missing information. Items assessed are described and listed in the headings 
below. 
Two review authors (AGM and OPN) assessed independently the quality of methodology of all 
included studies in the review.  As in previous phases, the opinion of a third review author (JPG) was 
obtained in case of disagreement.  
A study was considered as a RCT if it was explicitly stated as ‘randomized’. This should include the 
use of words such as ‘randomly’, ‘random’ or ‘randomization’.  
The randomized trial was then judged as 'truly random, pseudo-random, non-random or not stated'. 
A trial was defined as ‘truly-random’ if the allocation sequence was computer-generated or 
generated by a random number table, coin toss, shuffles or throwing dice. The person involved in 
the recruitment of participants should not be the one performing the procedure. 
If the selection was based on patient numbers, birth dates, visit dates, alternate allocation or other 
method not involving a defined random mechanism but likely to produce an unpredictable sequence 
of numbers, the trial was to be considered as ‘pseudo-random’. 
Studies were the selection was based on patient or clinical preference, or any selection mechanism 
that could not be described as random, were to be excluded. Also, studies that did not state whether 
the treatment was randomly allocated were to be excluded. 
3.4.5. Concealment of the treatment allocation at randomization 
A study was referred as concealed, unconcealed or unclear in the following situations.[37]
A study was considered ‘concealed’ if the trial lists were unaware of the allocation of each 
participant before they were entered in the trial. Adequate methods included central telephone 
randomization schemes, pharmacy-based schemes, sequentially numbered, opaque, sealed 
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envelopes, sealed envelope from a closed bag, or the use of numbered or coded bottles or 
containers. 
The allocation was ‘unconcealed’ when trial lists were aware of the allocation of each participant 
before they were entering the trial. For example when it was based on patient data, such as date of 
birth or hospital case note number, visit dates, sealed envelopes that were not opaque, or a random 
number table that was not concealed from the investigator. 
If authors did not report or provide a description of an allocation concealment approach that 
allowed for classification as concealed or not concealed then the study was categorized under 
‘unclear allocation concealment’. 
3.4.6. Implementation of masking 
A trial could be considered double-blinded, single-blinded, not blinded or unclear and was to be 
recorded within a risk of bias table into 3 categories: low risk, unclear risk and high risk.[33]
In the case of a trial was reported ‘double-blind’ it had to be flagged as ‘low risk’. Double blinding 
was however not expected to occur as per the type of treatment administration could not easily 
allow the blinding of the clinician, the outcome assessor, the participant and the pharmacist at the 
same time. 
 
A study was judged as ‘not blinded’ if the authors defined it as an open-label study. It was flagged as 
‘high risk’. 
Studies were to be categorized as ‘unclear risk’ if no blinding information was reported. 
If a trial was simply described as 'single-blind' the degree of masking was recorded as ‘unclear’ for 
clinician and outcome assessor when subjects were presumed blinded. 
3.4.7. Completeness of follow up and use of intention-to-treat (ITT) analysis 
The proportion of participants for which there were missing outcome data and/or who were 
excluded from the analysis were to be noted for each arm of the trial and in the ITT analyses these 
subjects were assumed to have failed therapy. It was stated whether the analysis included all 
randomized subjects that is, whether an ITT approach was undertaken. 
The authors’ definitions were recorded when they reported an ITT analysis. Due to the varied 
definitions of ITT by authors, the most accepted definition of the ITT approach was used. All subjects 
were to be analyzed in the groups to which they were originally randomly assigned, regardless of 
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whether they satisfied the entry criteria, whether the treatment was received, or subsequent 
withdrawal or deviation from the protocol was performed.[38]
3.5. Measures of treatment effect 
  
All available information for all randomized subjects was reported. Studies reporting either ITT or PP 
analysis alone were included. Authors of those primary studies either using a different ITT approach 
(as the one used in current meta-analysis) or reporting PP analysis only, were contacted in order to 
obtain the usual ITT analysis approach. 
Studies reporting ITT analysis but required subjects to have the second test confirming their H. pylori 
infection status after randomization in order to be included in the ITT analysis were equally included 
for the ITT meta-analysis. 
These four quality components were taken from the key methodological features that are important 
to the validity and interpretation of included trials as mentioned above. No quality score was given 
and studies classified as ‘low quality’ were not excluded. The individual quality assessment items 
were to be used to explore heterogeneity if significant heterogeneity between studies was shown 
(details below), by using subgroup analysis with pooled effect size estimated, and discuss them when 
interpreting the results. 
Dichotomous outcomes of individual studies were expressed as the odds ratio (OR) together with 
the 95% confidence interval (CI), taking 'H. pylori eradication' as the primary outcome. The OR 
describes the ratio of the odds of an event, for which a value of 1 indicates that the estimated 
effects are the same for both interventions.[33]
Meta-analysis was performed combining the ORs of the individual studies in a global OR using a 
fixed-effect (Mantel-Haenszel) method primarily, with the random-effects (DerSimonian and Laird) 
model used in addition as a sensitivity analysis to check the robustness of the results.
  
The sequential treatment arm was labelled as the treatment group and the standard triple therapy 
arm as the control group.  
[39, 40] Pooled 
effect estimations were performed using Review Manager 5.2 (RevMan 2012). 41[ ] All outcomes 
included in this review were binary. Data analyses were performed for each of the comparisons 
included.  
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There are several methods to calculate number needed to treat (NNT) and some have limitations.[42-
44]
Initially, the formula specified within the protocol document was NNT = 1/ [(1-RR) * CER]
 Many published meta-analyses do not provide the results or the methods used. In this report, the 
NNT was calculated for efficacy and the number needed to harm (NNH) for adverse events.  
[45]
3.5.1. Unit of analysis issues 
 where 
CER was the pooled control event rate. This formula was later modified and adapted to the measure 
of the effect size utilized in present review, i.e. odds ratio. The formula used was therefore NNT= (1-
(CER*(1-OR)))/ ((1-CER)*(CER)*(1-OR)). The NNT was always reported among those statistically 
significant comparisons, and where the OR was greater. 
Only standard design, parallel, randomized controlled trials were included. The interest was only in 
the direct comparison between the two treatment regimens. Multiple groups to a single pair-wise 
comparison were not included, so that the same patient was not used twice in the same analysis.  
However, multiple group comparisons are usual across treatment arms in clinical trials. For instance, 
the ITT population could be randomized into 3 different treatment arms (or schedules): standard 
triple therapy lasting 7 days, standard triple therapy lasting 14 days and sequential therapy lasting 
10 days. In such case, for the purpose of the overall analysis, the different arms of the same 
treatment (i.e. STT-7days and STT-14 days) were combined by summarizing the number of patients 
of each arm. Afterwards, the corresponding subgroup meta-analyses were undertaken. 
The patient was used as unit of analysis. The different treatment schedules within the same 
treatment arm were in addition further assessed through standard single pair-wise comparisons as 
specified under the subgroup analyses section. 
3.5.2. Dealing with missing data 
Authors were contacted for any incomplete outcome data from included studies. Those patients for 
whom outcome data were still missing (due to drop-out or incomplete records) were considered as 
to have failed eradication for the primary outcome. 
3.5.3. Assessment of heterogeneity 
In order to identify the possible diversity in trial characteristics, the clinical, methodological and 
statistical components were analyzed. 
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The Chi2 test for heterogeneity was carried out for each combined analysis, where p < 0.10 indicated 
significant heterogeneity between studies.[46] The I2 statistic, which quantifies heterogeneity by 
calculating the percentage of total variation across studies that is due to heterogeneity (an approach 
that has recently been endorsed by the Cochrane Collaboration) was reported. Significant 
heterogeneity was defined as I 2 > 25% based on the judgment that I2 values below 25%, 50% and 
75% represent low, moderate and high heterogeneity, respectively. 47[ ]
 Graphical methods (forest plots) were used to complete the Chi
 
2 test assessment. When 
heterogeneity was identified the source was investigated using further techniques, such as subgroup 
analyses or funnel plots, to work out whether particular characteristics of studies were related to the 
sizes of the treatment effect, according to the Cochrane Handbook for Systematic Reviews of 
Interventions.[33]
3.5.4. Assessment of reporting biases 
 
To assess publication bias, funnel plot asymmetry was inspected visually by examining the 
relationship between the treatment effects and the standard error of the estimate. Funnel plots 
were produced for the principal outcome for each comparison (plots of OR against the standard 
error (log of OR)).  
3.5.5. Data synthesis 
In order to collate, combine and summarize the information from the included studies, it was 
decided to undertake a quantitative (meta-analysis) approach. If there were insufficient trials (≤ 2) 
reporting for the same comparison, then a qualitative (narrative) evaluation was performed. 
As first step for the data synthesis, an initial overview of results was presented referring generally to 
all included studies (see 4.1.1). These overall findings were presented in a descriptive fashion in 
terms of geographic region, target populations, sample sizes, age of the population, medical 
condition at baseline and treatment schedules assessed.  
The second step in the evidence synthesis consisted of summarizing the information related to the 
size of the effect of the intervention for all studies as well as for each different participant group, 
comparison or outcome measure undertaken. Results from subgroup analyses as well as sensitivity 
analyses were also reported. 
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3.5.6. Subgroup analysis and investigation of heterogeneity 
Pre-planned, a priori, subgroup analyses were performed regardless of whether significant 
heterogeneity was present on the subgroups of: 
• geographic region; 
• publication date; 
• age (children versus adults); 
• length of standard triple therapy (7 versus 10 versus 14 days); 
• type of nitroimidazole (metronidazole versus tinidazole); 
• dosing for each antibiotic; 
• resistance of each antibiotic; 
• PPI type and dosing (new versus old generation); 
• type of disease at enrolment (PUD versus NUD); 
• other aspects of study quality: methods of randomization, concealment of allocation versus 
unconcealed/unclear , blinding; and 
• publication status (abstract format versus full-article format) which was additionally added 
as it was not initially stated in the protocol 
3.5.7. Sensitivity analysis 
No arbitrary inclusion or exclusion criteria were established for the search strategy. If during the 
review process sensitivity issues were identified (missing data, individual peculiarities of the studies) 
the meta-analysis was repeated using the different assumptions made.  
Sensitivity analyses were performed to test the robustness of the review: using a random-effects 
model instead of a fixed-effect model; excluding trials with no or unclear allocation concealment; 
excluding trials where the method of randomization was unclear; or excluding trials where masking 
was unclear. 
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4. Results 
4.1. Description of studies 
4.1.1. Results of the search 
A total of 4,795 citations were retrieved from the following electronic databases: Ovid (Medline), 
EBM Reviews - Cochrane Central Register of Controlled Trials, CINHAL and Embase, while 14 
additional references were identified through hand-searches and from the International Workshop 
of the European Helicobacter Study Group, the American Digestive Disease Week (DDW) and the 
United European Gastroenterology Week (UEGW) Congresses up to May 2013. 
After removal of duplicates, 4,173 citations resulting from the electronic searches only were initially 
screened. Based on the review of their corresponding titles and abstracts 4,142 citations were 
excluded, while 31 full papers were aimed to be retrieved, either because they were potentially 
relevant, or because not enough information was reported in the title and abstract to make a final 
decision regarding the inclusion of the paper in the systematic review. 
After review of the full papers, 30 publications were finally included in the systematic review: 16 
references from the electronic database searches and 14 resulting from the hand-searches.  All of 
them were randomized controlled trials (RCTs). 
A description of the process followed for the identification and selection of studies, and the number 
of studies identified through each step, is presented as part of the PRISMA diagram (Figure 1). 
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Figure 1. Study flow diagram 
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4.1.2. Included studies 
A total of 30 RCTs with standard parallel group designs were finally included in current systematic 
review. 
The primary objective of almost all the included studies was very similar and aimed to assess the 
efficacy of the 10 day sequential therapy (SEQ) over the standard triple therapy (STT).  
 
Only 2 references reported different primary objectives: the article published by De Francesco in 
2004 (b)[48] aimed to identify predicting factors for the outcome of H. pylori eradication using two 
therapeutic schemes (triple and sequential) and the article by Molina-Infante, 2010 49[ ]
Of the included studies, 11 were published in Italy
 whose 
primary objective was to compare clarithromycin and levofloxacin in triple and sequential first-line 
regimens.  
 
For the purposes of the evidence synthesis, the included studies were categorized according to the 
relevant endpoint assessed, i.e. the overall eradication rate with SEQ and STT as well as the different 
variables evaluated within the subgroup analysis.  
 
[48, 50-59], 6 in Korea 25[ , 60-64], 5 in China 65-69[ ], and one 
each in Iran, 70[ ] Latin-America, 71[ ] Poland, 72[ ] Puerto-Rico, 73[ ] Belgium 74[ ], Morocco 75[ ], India 76[ ] and 
Spain. 49[ ]
Three studies 
 Nine of the included studies were published before 2008.  
[69, 72, 74]
Eleven studies
 published between 2010 and 2011 assessed the efficacy of 10-day SEQ versus 
STT in children. 
[48, 49, 56, 58, 59, 61, 62, 68, 70, 71, 76]
The sample sizes across the included studies varied considerably ranging from 36 patients within the 
STT arm and 40 patients within the SEQ arm in the study by Lu, 2010
 assessed the efficacy of SEQ versus STT in both NUD and 
PUD patients´ groups. Cure rates were reported for each of the groups independently and the 
studies were pooled within the corresponding subgroup analysis.  
[69] to 522 patients within the 
SEQ arm and 527 patients in the STT arm in the study by Zullo in 2003. 59[ ]
All studies compared 10-day SEQ versus the STT. The STT included different regimens’ lengths (7, 10 
and 14-days) and different antibiotic doses (high and standard doses). The SEQ utilized different 
nitroimidazole types (metronidazole and tinidazole), and both regimens varied the type and dosage 
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of PPIs: omeprazole, lansoprazole, pantoprazole, rabeprazole, or esomeprazole. One study[54] used 
double-dose PPI and another 61[ ]
Further details on the different interventions evaluated across included studies are reported in 
 low-dose PPI in both treatment arms. 
Table 
2. 
4.1.3. Excluded studies 
The total number of studies finally excluded after both the first and second screenings was 4,157. 
In almost 50% of the cases, studies were excluded as they were not RCTs and 34% of the studies 
were discarded as they did not compare the pre-specified therapies (Table 1). 
Table 1. Reasons for excluded studies. 
Reason for exclusion Number % 
Not in humans 20 0.42 
Abstracts that were reported elsewhere 11 0.23 
Not an RCT  2,353 49 
Not H. pylori 116 2.4 
Not SEQ vs. STT 1,651 34 
Previous eradication therapy 3 0.06 
Not the outcome of interest 1 0.02 
Not retrieved* 2 0.04 
Total 4,157 100 
*References could not be accessed 
 
4.2. Effects of intervention 
4.2.1. Overall H. pylori eradication rate 
A total of 30 studies were finally included in the overall analysis comparing SEQ versus STT (summary 
Table 2).  
Note that for the overall analysis, when combining data and only within the STT arm, several studies 
did randomize patients into up to 3 different STT arms (7, 10 and 14 days). In order to preserve 
randomisation and weight among included studies, the final proportion of patients cured with STT 
was calculated into a single figure, by adding the number of patients cured in each of the 3 STT arms 
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(as stated in the section ‘Unit of analysis issues’). Then the total of events (total STT cure rate) was 
divided over the total of patients assessed within the 3 STT arms.  
The meta-analysis showed that in the ITT analysis, overall eradication rate was higher with SEQ than 
with STT (OR= 2.06; [95%CI= 1.59-2.66]; p<0.001; Figure 2). The NNT for the H. pylori overall ITT 
eradication rate was calculated as 9.  
Results were highly heterogeneous (I2
On the other hand, two studies
= 78%), therefore a random effect model was considered more 
appropriate to combine the dichotomous outcomes of the different studies.  
[70, 71]
Also, 10 of the included studies could not demonstrate any clinical benefit from one regimen over 
the other. Seven of the 10 aforementioned studies were performed in Asia (China and Korea), 1 in 
Puerto Rico,
 demonstrated a significantly higher efficacy with STT. Both of 
the studies assessed adult patients: the study by Aminian et al published in Iran in 2010 reported an 
ITT cure rate of 91% and 80% with STT and SEQ respectively. Similarly, the study by Greenberg et al 
published in 2011 as part of a multicentre trial in Latin America reported an ITT cure rate of 82% and 
76% with STT and SEQ respectively. 
[73] another 74[ ] was published as part of a multicentre trial involving Western European 
countries (France, Belgium and Italy) and another study 53[ ] was performed in Italy. 
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Figure 2. Forest plot of comparison: SEQ vs. STT, overall outcome: Eradication rate 
 
 
H. pylori eradication rate with SEQ ranged from 45% in the Chinese study by Wu performed in 
2011[66] to 96% in the Italian study by Focareta in 2002 51[ ]
The trend-line, expressed as the polynomial function of both SEQ and STT eradication rates showed 
how SEQ cure rates fluctuated before and after 2008 (
 (Table 2). 
Figure 3). An order 4 polynomial trend-line (4 
bends) has been used to illustrate the relationship between SEQ cure rates and the year of the 
publication of the studies. The polynomial function of SEQ was defined by: y= -0.0004x4 + 0.0273x3 - 
0.5431x2 + 2.3047x + 92.793; where R2= 0.385 showing an acceptable fit of the line to the data. The 
valley in the curve of SEQ shows a decrease in eradication rates below 90% from year 2008 but for 3 
studies which cure rates were greater or equal to 90%.[54, 69, 75]
Equally, an order 4 polynomial trend-line was chosen to illustrate the trend in eradication rates with 
STT through the time and to compare such curve with SEQ trend-line. The polynomial function of STT 
was defined by: y = 0.0003x4 - 0.0178x3 + 0.3028x2 - 2.3484x + 83.24; where R
  
 
2= 0.2015. As shown 
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in the graph (Figure 3), the absolute difference in eradication rates between SEQ and STT are lower 
between years 2010 and 2011. 
  
Similarly the linear weighted regression chart (Figure 4) presented the same tendency into a lower 
efficacy through the years in the overall mean eradication rate for both therapies. As stated, the 
regression is controlled by each study weight so that both spatial trends and spatial autocorrelation 
between eradication rates is accounted within the usual statistical assumptions of regression. A 
stronger trend from the same year 2008 onwards was highlighted. 
Moreover, cure rates with SEQ appeared constant and continuous among the Italian studies 
published before 2008 whereas this un-interrupted level of eradication achieved ceased from year 
2008 (Figure 5).  
In total, eleven (37%) studies performed in Italy showed that ITT eradication rates with SEQ were 
over 90%; whereas in the remaining studies ITT rates were mostly below this threshold (Figure 3 and 
Figure 6). 
 
Figure 3. Efficacy of 10-day SEQ vs. STT by included study and publication date 
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Figure 4. Ten-day SEQ and STT linear weighted regression by publication date*  
 
*The ‘x’ axis represents the year of publication of the study. For instance ‘2’ and ‘12’ state for year 2002 and year 2012, 
respectively.  
The ‘y’ axis represents the eradication rate (%) in the corresponding treatment arm. 
 
Figure 5. ITT eradication rates (%) with 10 day SEQ through the time 
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Table 2. Studies evaluating the efficacy of SEQ 
First author Country Year of 
publication 
Disease 
type 
Therapy regimen Total nº patients ITT eradication rate (%) 
Focareta Italy 2002 PUD and 
NUD 
O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
94 95.7 
Focareta Italy 2003 PUD and 
NUD 
E 20 mg b.i.d. + A 1 g b.i.d. 5 d 
E 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
174 95.4 
Zullo Italy 2003 PUD R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
522 92.1 
De Francesco 
(a) 
Italy 2004 PUD and 
NUD 
R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
45 95.5 
De Francesco 
(b) 
Italy 2004 PUD R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
116 94.8 
Zullo Italy 2005 PUD R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
89 94.3 
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Scaccianoce Italy 2006 NUD E 20 mg b.i.d. + A 1 g b.i.d. 5d 
E 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
72 94.4 
Vaira Italy 2007 PUD P 40 mg b.i.d. + A 1 g b.i.d. 5 d 
P 40 mg b.i.d.+ C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
150 89.3 
Choi Korea 2008 PUD O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
77 77.9 
Paoluzi Italy 2010 N.R E 20 mg b.i.d. + A 1g b.i.d. 5 d 
E 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
90 86.6 
Molina-Infante Spain 2010 PUD O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
115 76.5 
Aminian Iran 2010 NUD O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
107 80.3 
Gao China 2010 PUD O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
72 88.8 
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Lu China 2010 PUD and 
NUD 
O 0.8 mg / kg / day + 
A 40 mg / kg / day 5 d 
O 0.8 mg / kg / day + 
A 40 mg / kg / day 5 d + 
C 15 mg / kg / day + 
T 15 mg / kg / day 5 d 
40 90 
Yan China 2011 N.R E 20 mg b.i.d. + A 1g b.i.d. 5 d 
E 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
246 75.2 
Lopez-Román Puerto Rico 2011 N.R O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
41 65.8 
Franceschi Italy 2011 N.R L 15 mg b.i.d. + A 1g b.i.d. 5 d 
L 15 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
50 72 
Bontems Belgium 2011 PUD O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
83 81.9 
Albrecht Poland 2011 N.R O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
52 86.5 
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Wu China 2011 NUD and 
PUD 
E 20 mg b.i.d. + A 1 g b.i.d. 5 d 
E 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
102 45 
Greenberg Latin 
America 
2011 NUD L 30 mg b.i.d. + A 1 g b.i.d. 5 d 
L 30 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
486 76.5 
Kim Korea 2011 PUD P 40 mg b.i.d. + A 1 g b.i.d. 5 d 
P 40 mg b.i.d.+ C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
205 85.8 
Gatta Italy 
 
2011 NUD and 
PUD 
E 40 mg b.i.d. + A 1 g b.i.d. 5 d 
E 40 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
131 94.6 
Chung Korea 2012 PUD L 30 mg b.i.d. + A 1 g b.i.d. 5 d 
L 30 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
79 75.9 
Oh Korea 2012 PUD and 
NUD 
R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
116 79.3 
Choi Korea 2012 PUD and 
NUD 
R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
115 75.6 
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Park Korea 2012 PUD and 
NUD 
R 20 mg b.i.d. + A 1 g b.i.d. 5 d 
R 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
162 77.7 
Lahbabi Morocco 2012 PUD and 
NUD 
O 20 mg b.i.d. + A 1 g b.i.d. 5 d 
O 20 mg b.i.d. + C 500 mg b.i.d. 
+ M 500 mg b.i.d. 5 d 
104 94.2 
Javid India 2013 PUD P 40 mg b.i.d. + A 1g b.i.d. 5 d 
P 40 mg b.i.d.+ C 500 mg b.i.d. 
+ T 500 mg b.i.d. 5 d 
138 76 
Liou China 2013 PUD L 30 mg b.i.d + A 1 g b.i.d. 5 d 
L 30 mg b.i.d + C 500 mg +  
M 500 mg b.i.d. 5 d 
300 87 
ITT: intention-to-treat. RCT: randomized controlled trial. PUD: peptic ulcer disease; NUD: non-ulcer disease. PPI: proton pump inhibitor; O: omeprazole; L: lansoprazole; P: pantoprazole; R: 
rabeprazole; E: esomeprazole; A: amoxicillin; C: clarithromycin; M: metronidazole; T: tinidazole; d: days; b.i.d.: two times a day; t.i.d: three times a day; N.R.: not reported 
 
In order to assess in detail the impact of different variables in the eradication rate among included trials, several subgroup analyses were performed 
(section 4.2.2). 
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4.2.2. Effects of different variables on the efficacy of sequential therapy 
(SEQ) vs. standard triple therapy (STT) 
As shown in the headings below, the efficacy of the SEQ might have been influenced by several 
factors.  
4.2.2.1. Geographic region 
Around one third (37%) of the studies included in current meta-analysis were performed in Italy. 
Although sequential regimen was superior to standard triple regimen in both subgroup analyses 
(Figure 6), a greater effect size (OR 4.09 vs. 1.48) as well as a clear tendency towards higher 
eradication rates with SEQ was confirmed among the Italian publications (92% vs. 79%).  
The NNT among the Italian studies was 6 whereas within non-Italian studies it was calculated as 15. 
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Figure 6. Forest plot of comparison: SEQ vs. STT, outcome: Geographic region 
 
 
4.2.2.2. Publication date 
Following the analysis of the eradication rate trend mentioned in the heading above (4.2.1 Overall H. 
pylori eradication rate), the year 2008 was chosen as the threshold to perform a sub-analysis 
accounting for the timing of the publication of the included studies.  
As stated, the overall eradication rate following SEQ showed a tendency into a lower efficacy from 
year 2008 (Figure 3 and Figure 5). Additionally, the eradication rates before year 2008 appeared 
constant (or similar) between studies but after year 2008 cure rates were shown irregular or even 
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puzzled through the time as represented by the various plots around the trend-line between 2008 
and 2012 (Figure 4). 
The forest plot (Figure 7) also presented the aforementioned differences in the eradication rates of 
the studies performed before and after year 2008.  
Before 2008, studies reported higher eradication rates and the overall effect size of the estimate was 
almost 2.5 times greater than among studies published after 2008 (OR 3.63 vs. 1.64). The NNT within 
the subgroup of studies ‘before 2008’ and ‘after 2008’ was 7 and 12 respectively. 
Moreover, all the studies published before the chosen year-cut-off point were performed in Italy 
(but one published in Korea)[25] and heterogeneity was reported moderate (I2= 29%) whereas in 
studies published after 2008 it was reported higher (I2=73%). It was decided to include the Korean 
study within this ‘before 2008’ group as it seemed more coherent given the chronological sequence 
of published articles.  
Further sensitivity analysis, first including all studies and second excluding the Korean trial showed 
very similar effect size (OR 4.11 vs. 3.63) for this subgroup and no heterogeneity was recorded (I2
Differences between SEQ and STT were significant in all Italian studies but in the Korean study 
mentioned (Choi et al, 2008) in which significant differences between therapies were not reported.  
Additionally, two Italian studies
= 
0). This analysis indicated certain robustness in the findings towards the decisions made.  
[54, 55]
 
 
 
 
 
 reported a significantly larger effect size of SEQ over STT in the 
‘after 2008’ subgroup. 
In order to prove findings were not result of arbitrary decisions, the meta-analysis was doubled and 
primary analysis was substituted by pooling only the data of the studies published ‘after 2008’. The 
effect size indeed was lower (OR 1.55 vs. 2.02) however the clinical benefit with SEQ over STT could 
still be verified. 
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Figure 7. Forest plot of comparison: SEQ vs. STT, outcome: Publication date 
 
 
4.2.2.3. Age of the population 
All included studies but 3[69, 72, 74]
The pooled OR for eradication of H. pylori with SEQ compared to STT in children was reported 
slightly higher than in adults (OR 2.31 vs. 2.18; 
 assessed adult patients and studies assessing children were first 
published in 2010 onwards. 
Figure 8). The NNT was 8 in children and 9 in adults. 
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Figure 8. Forest plot of comparison: SEQ vs. STT, outcome: Age of the population 
 
 
4.2.2.4. Type of underlying disease: non-ulcer disease (NUD)  vs. peptic ulcer 
disease (PUD) 
Eleven studies reported the baseline medical condition of patients. A total of 1,542 and 2,293 
patients were assessed in the PUD and NUD subgroups, respectively.  
Data of the present meta-analysis suggest that eradication rates following SEQ in both ulcer patients 
and non-ulcer patients were equal (86%) but differences between SEQ and STT were significant only 
among PUD patients (OR= 2.17; [95%CI= 1.07-4.41]; p<0.001) in which SEQ could demonstrate to be 
more effective (Figure 9). The NNT among PUD and NUD patients was 7 and 11 respectively. 
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Figure 9. Forest plot of comparison: SEQ vs. STT, outcome: Medical condition 
 
 
4.2.2.5. Length of the standard triple therapy (STT) 
Sixteen, 11 and 5 studies assessed respectively 7-day, 10-day and 14-day STT vs. 10-day SEQ. 
Eradication rates and ORs are summarized in Table 3. 
Table 3. Efficacy of 7-day, 10-day and 14-day STT vs. 10-day SEQ 
 7-d STT vs. 10-d SEQ 10-d STT vs. 10-d SEQ 14-d STT vs. 10-d SEQ 
ITT eradication rates (%) 72.5 vs. 88.5 73.9 vs. 81.8 77.9 vs. 77.6 
OR [95%CI] 2.93 [2.31, 3.87]* 1.81 [1.26, 2.60]* 1.09 [0.72, 1.75], NS 
STT: standard triple therapy; SEQ: sequential therapy; OR: odds ratio.   
*Differences were significant between treatment groups. N.S: non-significant differences 
SEQ was significantly better than 7-day and 10-day standard triple therapies but differences 
between 14-day STT and 10-day SEQ were not observed (p=0.67; Figure 10). The NNT within both 
the STT 7-day and STT – 10 days subgroup was 7 and 11 respectively.   
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Figure 10. Forest plot of comparison: SEQ vs. STT, outcome: STT length 
 
 
4.2.2.6. Type of nitroimidazole 
Fourteen and 16 studies used metronidazole and tinidazole respectively in patients treated with 
SEQ.  
The subgroup analysis showed that SEQ was significantly better than STT when patients were 
treated with either metronidazole or tinidazole. However, the effect size when patients were given 
tinidazole was higher than in those treated with metronidazole (OR 2.72 vs. 1.76), suggesting a 
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benefit of this drug with SEQ (Figure 11). The NNT among both the tinidazole and metronidazole 
subgroup was 7 and 11 respectively. 
Figure 11. Forest plot of comparison: SEQ vs. STT, outcome: Nitroimidazole type 
 
 
4.2.2.7. Proton-pump inhibitor (PPI) type and dosing 
Both STT and SEQ used different PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, or 
esomeprazole) as well as different PPI doses among the included studies.  
A subgroup analysis was performed to compare the efficacy of adjuvant medication within both 
treatment regimens. Studies in the ‘new generation PPIs’ group used either esomeprazole or 
rabeprazole and studies in the ‘old / first generation PPIs’ used omeprazole, lansoprazole or 
pantoprazole. Fourteen studies (46%) assessed the new generation of PPIs and the rest evaluated 
first/old generation PPIs. 
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The data presented SEQ as more effective than STT using the new PPI generation (esomeprazole or 
rabeprazole) than when patients were given a first PPI generation (omeprazole or pantoprazole) (OR 
2.70 vs. 1.70; Figure 12). 
The number needed to treat within studies using the new generation PPIs was 7. 
Regarding dosage, almost all studies used standard doses (20 mg twice daily) for omeprazole, 
rabeprazole or esomeprazole as well as for pantoprazole (40 mg twice daily) and lansoprazole (30 
mg twice daily). One Italian study[54] used esomeprazole at double-doses (40 mg twice daily) in an 
adult population. Another Italian study 53[ ]
Figure 12. Forest plot of comparison: SEQ vs. STT, outcome: PPI type 
 used low-dose lansoprazole (15 mg twice daily) in both 
treatment arms. 
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4.2.2.8. Antibiotic resistance 
Clarithromycin, nitroimidazole and the dual clarithromycin and nitroimidazole resistances did not 
result in significant differences in any of the subgroup analyses between both regimens’ eradication 
rates (Figure 13). 
Despite antibiotic resistances, when assessing the total of patients for whom antibiotic resistances 
had been assessed (273 in the SEQ arm and 268 in the STT arm), SEQ was significantly more 
beneficial than STT (OR= 2.42; [95%CI 1.05-5.58]; p=0.04).  
Moreover, patients with clarithromycin-resistant strains showed a greater benefit of SEQ over STT 
than in the remaining subgroup analyses assessing antibiotic resistance. Additionally, the effect 
estimate within the clarithromycin resistance subgroup analysis was also reported greater if 
compared to the effect estimate of the overall eradication rate analysis (OR 4.20 vs. 2.12), meaning 
differences between treatment arms were even greater among those patients with primary 
resistances. 
On the other hand, the subgroup analysis evaluating patients with nitroimidazole-resistant strains 
presented no differences between treatments but patients could benefit more from SEQ (87%) than 
with STT (82%) and eradication rates among patients with secondary resistances were higher in both 
treatment arms than in those patients with primary resistances. However, the effect size was 
reported lower than in those with clarithromycin-resistant strains (OR 1.74 vs. 4.20). 
Patients with dual clarithromycin and nitroimidazole resistance did not report significant differences 
between SEQ and STT, although eradication rates with SEQ (80%) were greater than with STT (67%). 
Figures regarding antibiotic susceptibility were not available among most of the studies reporting 
resistance; and therefore data could not be pooled into the corresponding forest plot.  Only two 
studies,[57, 68]
Table 4. Reported antibiotic susceptibilities by treatment arm 
 reported antibiotic susceptibility for clarithromycin, nitroimidazole and the 
combination of both (Table 4). 
  clarithromycin-S nitroimidazole-S clarithromycin and nitroimidazole-S 
  SEQ STT SEQ STT SEQ STT 
Vaira 2007 108 / 114 86 / 91 83 / 88 72 / 90 N.R N.R 
Liou 2013 152 / 166 137 / 151 130 / 139 107 / 125 123 / 129  98 / 109 
S: susceptibility. N.R. not reported  
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Figure 13. Forest plot of comparison: SEQ vs. STT, outcome: Antibiotic resistance 
 
 
4.2.2.9. Compliance and tolerance 
Twenty-two (73%) studies described common adverse events (AEs) such as abdominal pain, 
diarrhoea, nausea, glossitis and vomiting and their incidence by treatment arms. None of the studies 
reported any serious AE (Table 5). 
Within the SEQ arm the incidence of AEs ranged from 7% in the study by Zullo in 2003[59] to 54% in 
the study by Paoluzi in 2010, 55[ ] whereas within the STT the incidence ranged from 2% in the study by 
Aminian in 2010 70[ ] to 55% in the study by Liou in 2013. 68[ ]
In the ITT analysis, the overall adverse event rate (
 
Figure 14) showed no significant differences 
between SEQ and STT (18% in both treatment arms; OR= 0.96; [95%CI=0.84-1.10]; p=0.56). Results 
were homogeneous (I2=11%), therefore a fixed effect model was used as appropriate. None of the 
studies was able to demonstrate differences between therapies’ side effects.  
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Similar compliance rates were reported among the 22 studies but for the study published by Park et 
al in 2012[64] rates were reported lower: 72% and 58% with SEQ and STT respectively. With the 
exception of the aforementioned study, compliance rates ranged as follows:  from 85% in the study 
by Aminian et al in 2010 70[ ] to 97% in the study by Kim et al in 2011 62[ ] with SEQ and from 81% in the 
study by Liou et al in 2013 68[ ] to 97% in the study by Kim et al in 2011 62[ ]
Overall, AEs required the interruption of therapy in 18 patients out of a total of 596 (3%) 
experiencing AEs in the SEQ arm and in 35 out of 664 (5%) in the STT arm (
 with STT. 
Table 5). 
Figure 14. Forest plot of comparison: SEQ vs. STT, outcome: adverse events. 
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Table 5. Compliance, AEs and withdrawals (due to AEs) within both treatment arms 
  Compliance rate (%)* AEs rate (%) Withdrawals rate (%) due to AEs 
First author Year  10d- SEQ 7d- STT 10d- STT 14d- STT 10d- SEQ 7d- STT 10d- STT 14d- STT 10d- SEQ 7d- STT 10d- STT 14d- STT 
Zullo 2003 
456 / 522 
(90) 
471 / 527 
(93) 
    
36 / 522 
(7) 
45 / 527 
(9) 
    
0 / 522 
(0) 
1 / 527 
(0.2) 
    
Zullo 2005 > 95% > 95%     
9 / 89 
(10.1) 
10 / 90 
(11.1) 
    
1 / 89 
(1.1) 
2 / 90 
(2.2) 
    
Scaccianoce 2006 > 95% > 95% > 95 %   
8 / 72 
(11.1) 
7 / 70 
(10) 
9 / 71 
(12.7) 
  
2 / 72 
(2.7) 
 2 / 70 
(2.8) 
 2 / 71 
(2.8) 
  
Vaira  2007 
135 / 150 
(90)** 
  
135 / 150 
(90)** 
  
25 / 150 
(16.6)** 
  
25 / 150 
(16.6)** 
  
0 / 150 
(0)** 
  
1 / 150 
(0.6)* 
  
Choi 2008 N.R N.R     
22 / 77 
(28.6) 
24 / 81 
(29.6) 
    N.R N.R     
Paoluzi 2010 > 90% > 90 %     
34 / 90 
(54) 
25 / 90 
(42) 
    
3 / 90 
(3.3) 
2 / 90 
(2.2) 
    
Molina-
Infante 
2010 
111 / 115 
(96.5) 
114 / 115 
(99.1) 
    
29 / 115 
(25) 
29 / 115 
(25) 
    
1 /115 
(0.8) 
1 / 115 
(0.8) 
    
Gao 2010 > 95% > 95%     
14 / 72 
(19.4) 
11 / 71 
(15.5) 
    0 / 72 (0) 0 / 71 (0)     
Aminian 2010 > 85%   > 85%   
2 / 107 
(1.9) 
  
2 / 107 
(1.9) 
  N.R   N.R   
Lu 2010 N.R    N.R   
7 / 40 
(17.5) 
  
6 / 36 
(16.6) 
   N.R   N.R   
Albrecht 2011 > 95% > 95%     
10 / 52 
(19.2) 
9 / 51 
(17.6) 
    0 / 52 0 / 51     
Franceschi 2011 N.R N.R     
12 / 50 
(24) 
21 / 100 
(21) 
    N.R N.R     
Kim 2011 
199 / 205 
(97)** 
    
199 /204 
(97.5)** 
36 / 205 
(17.5)** 
    
24 / 204 
(11.7)** 
0 / 205 
(0) 
    
0 / 204 
(0) 
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Greenberg  2011 
427 / 486 
(87.8)** 
    
437 / 488 
(89.5)** 
33 / 486 
(6.7)** 
    
41 / 488 
(8.4)** 
N.R     N.R 
Bontems 2011 N.R N.R     
37 / 83 
(44) 
31 / 82 
(37.8) 
    N.R N.R     
Choi 2012 > 95% > 95% > 95% > 95% 
15 / 115 
(13) 
11 / 115 
(9.5) 
14 / 115 
(12.1) 
12 / 115 
(10.4) 
N.R N.R N.R N.R 
Oh 2012 > 90% > 90%     
32 / 116 
(27.5) 
31 / 130 
(23.8) 
    
0 / 116 
(0) 
0 / 130 
(0) 
    
Park 2012 
116 / 162 
(71.6) 
95 / 164 
(57.9) 
    
40 / 162 
(24.7) 
35 / 164 
(21.3) 
    
2 / 162 
(1.2) 
2 / 164 
(1.2) 
    
Chung 2012 
76 / 79 
(96.2) 
  
77 / 80 
(96.2) 
  
21 / 80 
(26.3) 
  
23 / 79 
(29.1) 
  
3 / 79 
(3.8) 
  
3 / 80 
(3.7) 
  
Lahbabi 2012 
98 / 104 
(94.2) 
106 / 115 
(92.2) 
    
10 / 104 
(9.6) 
32 / 115 
(27.8) 
    0/104 
5 / 115 
(4.3)  
    
Javid 2013 
121 / 124 
(97.6) 
  
121 / 123 
(98.4) 
  
22 / 124 
(17.7) 
  
23 / 123 
(18.7) 
  0/124   
1 / 123 
(0.8) 
  
Liou  2013 
258 /300 
(95) 
  
243 / 300 
(81) 
  
142 / 300 
(47.3) 
  
164 / 300 
(54.6) 
  
6 /300 
(2) 
  
13 /301 
(4.3) 
  
Striped pattern cells show when treatment arm was not in the trial.  
N.R.: Not reported in the publication 
* as defined by authors (usually good if >90% or >95% of drug intake) 
* Kim, 2011 reported PP compliance rates, SEQ 184 / 190 (96.8) and 14d-STT: 175 / 180 (97.2). 
AEs were also as per protocol rates, SEQ: 36 / 190 (18.9) and 14d- STT: 24 / 180 (13.3) 
** Vaira, 2007 reported PP compliance rates, SEQ: 135 / 143 (94) and STT: 135 / 146 (93). AEs 
were also PP rates, SEQ: 25 / 143 (17.5) and STT: 25 / 146 (17.1) 
** Greenberg, 2011 reported PP compliance rates, SEQ: 427 / 475 (97) and STT: 437 / 470 (93). 
AEs were also reported PP rates, SEQ: 33 / 470 (7) and STT: 41 / 475 (9) 
** Park, 2012 reported PP compliance rates, SEQ: 116 / 132 (87.9) and STT: 95 / 125 (76). AEs 
were also reported PP rates, SEQ: 40 / 143 (28) and STT: 35 / 137 (25.5) 
** Liou, 2013 reported PP compliance rates, SEQ: 258 /285 (91) and STT: 243 / 278 (87). AEs 
were also reported PP rates, SEQ: 142 / 294 (48) and STT: 164 / 198 (55) and PP withdrawals 
rates (due to AEs) as, SEQ:  6 /295 (2) and STT: 13 /297 (4) 
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4.3. Risk of bias in included studies 
In the overall comparison ‘eradication rate of SEQ vs. STT’, two[57, 72]
Two studies,
 studies out of 30 were 
categorised as ‘low risk of bias’ in all 4 items of the checklist assessing the quality of the 
methodology (Figure 16).  
[69, 74] were categorised as ‘high risk’ in the items relating to randomisation, allocation 
and blinding. Two other studies 55[ , 64]
Lack of comprehensive reporting of outcomes as well as scarcity in the report of the information 
related to the assessed quality-items within the aforementioned studies, made both selection and 
performance biases a threat to the validity of the review (
 were likewise flagged as having poor allocation concealment 
and blinding.  
Figure 15 and Figure 16).  
However, regardless of the potential biases, the subgroup analyses confirmed a significant gain in 
the ITT eradication rate with 10-day SEQ compared to STT (4.3.1 Allocation and 4.3.2 Blinding). 
Figure 15. Risk of bias: review authors' judgements about each risk of bias item presented as 
percentages across all included studies 
 
 
Most of the studies (63%) were reported as ‘truly randomized’ and were unlikely to have been 
subject to selection bias due to a lack of randomization of the sequence generation.  
Performance bias due to lack of poor blinding of study participants and personnel was a priori the 
quality-item that was more likely to influence the review’s outcome as only per the quality 
assessment over 50% of studies were flagged as ‘high risk’. However, the importance of this finding 
in the context of H. pylori eradication is low, as will be analysed in the Discussion section. 
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Forest plot comparing the different subgroups in regards to the process of randomization across 
included studies is presented in Figure 17.  
Both Mantel-Haenszel odds ratios (ORs) in either ‘truly randomized’ (OR=2.21; [95%CI=1.59-3.07]; 
p<0.001) or ‘pseudo-randomized’ (OR=2.20; [95%CI=1.45-3.33]; p<0.001) subgroups showed that 
patients could benefit more from the SEQ versus the STT. 
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Figure 16. Risk of bias summary: review authors' judgements about each risk of bias item for each 
included study 
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Figure 17. Forest plot of comparison: SEQ vs. STT, outcome: Randomization  
 
 
4.3.1. Allocation 
Eighteen (60%) studies did not report any information on the allocation of the sequence generation 
and in 5 (17%) studies the sequence was reported as ‘not allocated’ (Figure 16). 
In order to generate unpredictable and unbiased sequence, 7 (23%) studies reported ‘adequate’ 
concealment of the allocation sequence mainly using opaque sealed envelopes and by involving 
personnel in the enrolment phase that were unaware of upcoming assignment of participants to 
treatments.  
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For instance, the study by Albrecht et al[72] published in 2011 reported that the intervention sets 
were prepared by the hospital’s pharmacy and by independent personnel not involved in the study. 
Similarly, in the trial by Kim et al 62[ ]
The 
 published in 2011, only the independent staff could manage a 
matching list between study identification number and hospital number and the data were revealed 
to other investigators once recruitment and data collection were completed.  
Figure 18 below shows that outcomes were unlikely to be influenced by any potential selection 
bias. 
Figure 18. Funnel plot of comparison: SEQ vs. STT, outcome: Allocation concealment 
 
Also, the forest plot comparing the interventions assessed for the outcome ‘allocation’ (Figure 19) 
showed that patients could benefit more from the SEQ versus the STT in both the subgroups’ 
analyses where the allocation was either concealed or unclear although a higher effect size was 
observed among studies with unclear allocation (OR 2.49 vs. 1.96). Additionally, no significant 
differences were found between treatments in studies were allocation was unconcealed (OR= 1.49; 
[95%CI= 0.50-4.40]; p<0.5). 
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Figure 19. Forest plot of comparison: SEQ vs. STT, outcome: Allocation concealment 
 
 
4.3.2. Blinding  
Regarding masking, 14 (47%) studies were adjudicated a ‘high risk’ category as authors reported 
either that the trial was not blinded or the design of the study was ‘open-label’. Similarly, other 14 
studies under the category ‘unclear risk’ either did not report any information regarding masking or 
authors stated that only the investigators (but not the patients), were blinded to the treatment 
allocation in that case studies were tracked single-blinded (Figure 16).  
Two studies[57, 72] were categorised ‘low risk’ given authors stated a ‘double-blind’ design was used 
with placebo during 3 days after completion of the STT. Being only two studies, no subgroup meta-
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analysis was performed with them as established in the protocol. The eradication rates were 
calculated as 89% and 86% in the SEQ arms and 77% and 69% in the STT arms in the studies by Vaira 
et al and Albrecht et al respectively. 
It should nonetheless be noted that the number of studies that were not blinded was a priori due to 
the design of the sequential regimen itself, where most of the times two drugs were used in the 
initial phase and three drugs during the second phase of treatment (as per protocol). As per such 
way of administering drugs in both of the regimens, participants could not be blinded in practical 
terms.  
However, the funnel plot below showed that outcomes were not influenced by bias associated with 
blinding, (Figure 20) and SEQ was reported to be more effective than STT regardless of the masking 
of the studies (OR= 2.43; [95%CI= 1.65-3.59]; p<0.001; Figure 21). 
 
Figure 20. Funnel plot of comparison: SEQ vs. STT, outcome: Masking 
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Figure 21. Forest plot of comparison: SEQ vs. STT, outcome: Masking 
 
 
4.3.3. Incomplete outcome data 
Primary outcomes were correctly and consistently reported in the majority (75%) of the studies 
(Figure 15). Attrition bias was reported in 2 of the 7 studies in abstract form[66, 73] accounting for 
around 1,709 patients, which represented 19% of the total of the randomized population in current 
meta-analysis. 
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Indeed, information related to the medical condition at baseline, sex ratio, average age of the 
population, PP sample size, incidence of AEs or antibiotic resistance were scarcely described in the 
reports of abstracts of Congresses.  
No difference in the number of excluded participants or drop-out was noted between arms across 
included studies. 
4.3.4. Selective reporting 
Five (18.5%) studies out of 30 evaluating antibiotic resistance; 4 reported the different cut-off points 
for isolates assessed to nitroimidazole, clarithromycin, and amoxicillin.  
Minimal inhibitory concentrations to consider resistance were reported as ≥8 µg/mL for 
metronidazole, ≥1 µg/mL for clarithromycin and between 0.5 and 1 µg/mL for amoxicillin across all 4 
studies. The remaining study was an abstract and the information was not available and could 
neither be retrieved from the authors.  
Therefore, bias associated with selective reporting of the aforementioned outcome measure 
seemed likely.  
4.3.5. Other potential source of bias 
Twenty-three (77%) studies were in complete article form. No bias due to the status of the 
publication was able to influence outcomes (Figure 22). SEQ was significantly more effective than 
STT in studies presented as full articles and abstracts but the effect size reported was slightly greater 
among trials presented as abstracts (OR 2.47 vs. 2.12; Figure 23). 
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Figure 22. Funnel plot of comparison: SEQ vs. STT, outcome: Publication Format 
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Figure 23. Forest plot of comparison: SEQ vs. STT, outcome: Publication Format 
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5. Discussion 
Multiple treatments have been suggested for H. pylori infection and that has been frequently 
reported and discussed in the literature. Despite the large number of studies performed in the last 
two decades, no optimal first-line eradication regimen has been yet defined. 
There could be many explanations but mainly efficacy, cost-effectiveness, toxicity and ease of 
administration of drugs as well as antibiotic resistance, have been reported among current 
challenges that need to be overcome.  
Main findings of the present systematic review 
The primary aim of this systematic review was to evaluate the efficacy of 10-day SEQ versus STT 
addressed in the available published RCTs. The secondary objective was to compare the incidence of 
AEs.  
The screening and full-text assessment of citations resulting from both the electronic and manual 
searches yielded the inclusion of 30 RCTs. All studies addressed treatment and compared 10-day SEQ 
versus 7, 10 or 14-day STT.  
From the included studies, 7 (23%) were published as abstracts from Congresses and/or Conferences 
and the subgroup analysis showed that although heterogeneity was high (I2=77%) among these 
studies, no bias was associated with the format of the publication neither the quality items assessed 
in the total of studies. This gave certain robustness to the findings of this systematic review.  
Among the other subgroup analyses, a high proportion of studies were published in Italy (n= 10), 
many others were published after 2008 (n= 22), very little evidence was published in children 
populations (n= 3), and pre-treatment antibiotic susceptibility and/or resistance were barely 
mentioned (n= 5).  
Overall, the efficacy of 10-day SEQ was higher than treatment with 7 or 10-day STT but no 
differences were found when 10-day SEQ was compared with 14-day STT.  
Overall efficacy of SEQ vs. STT 
The efficacy endpoint of interest collected was the H. pylori ITT eradication rate. From the 30 
included studies and a total of 8,878 patients, a mean H. pylori cure rate of 84% in the SEQ arm vs. 
74% in the STT arm was calculated.  
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The overall analysis proved a significantly higher efficacy of the SEQ over the STT supporting findings 
from previously published pooled data-analyses.[12, 23, 29, 31, 77-80] However, eradication rates in both 
SEQ and STT arms still remained lower (80-85%) than the optimal eradication levels (> 90-95%) 
required for microbial infections. 22[ ]
Findings of the current meta-analysis also showed a decreased efficacy of SEQ (and potentially STT) 
therapies through the last years. In fact, substantially decreased eradication rates (lower than 80%) 
by triple therapies have been reported in Europe,
  
[21, 48, 81] Asia, 82[ ] United Sates 18[ ] and Canada, 83[ ] and 
likewise some authors have proposed an eradication failure rate greater than 20%. 84[ ]
Lack of optimal treatment effect has been mainly attributed to antibiotic resistance. Many studies 
addressing eradication therapies for H. pylori infection have been published and included in new 
systematic reviews and meta-analyses.
 
[17, 85]
Additionally, the success or failure of antibiotic regimens has been also associated to a number of 
different factors such as: number of antibiotics used, poor compliance, type of underlying disease 
such as PUD or NUD, shorter vs. longer STT duration (7 vs. 10 vs. 14 days), drug-related AEs, previous 
stomach bacterial load, bacterial virulence (Cag A status), tobacco use, age of the population, 
geographical region, or any other variable that could predict or influence the treatment outcome.
 
[86]
A previous review published in 2010 by Gisbert et al
  
In the present meta-analysis, several subgroup analyses were performed in order to assess the 
impact of such factors in the efficacy of both SEQ and STT. Candidate hypothetical theories are 
presented in order to explain such differences. 
Variables influencing efficacy of SEQ 
Geographic region  
[31]
In the current systematic review, 11 studies were performed in Italy and all of them showed a 
significant and clear advantage of SEQ over STT. On the other hand, 9 (out of 17) studies published 
out of Italy could not find differences between therapies and those were mostly conducted in Asia 
where antibiotic resistances, especially nitroimidazole resistance, have been reported higher than in 
other settings. For instance, the World Gastroenterology Organization Global Guidelines (2011) 
reported that in China (2007) metronidazole and clarithromycin resistance rates reached 76% and 
28% respectively. Similarly, in Iran (2007) metronidazole and clarithromycin resistance rates were 
 showed that almost all studies comparing 
SEQ and STT therapies were performed in Italy, contributing to a lack of validation of findings in 
other settings.  
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73% and 9% respectively.[87]
In fact, as some authors have already postulated, the origin of the studies should not be considered 
that relevant. For the purpose of efficacy and antibiotic resistance analyses, it would be more 
reasonable to consider the site of the studies as a surrogate factor for a given pattern of efficacy (or 
resistance) rather than a direct predictor of efficacy outcome.
 Aforementioned figures could explain the results differences in studies 
conducted in such countries regarding data of Italian and in general European studies. 
Moreover, the subgroup analysis showed that all studies performed in Italy but 3 were published 
before 2008. Now, it could be argued that opposite phenomenon would be taking place in Italy given 
to the lack of findings’ validation in such setting through the most recent years.  
[88, 89]
Currently, a trend to lower H. pylori cure rates following STT has been suggested but more recently, 
an epidemiological analysis of all published Spanish trials revealed a rather constant eradication rate 
over the years.
  
Publication date 
In line with the geographic region factor, if one takes into account the year of publication of the 
included studies, a distinct trend toward a lower efficacy of SEQ was shown in studies published 
after year 2008 and mainly in those published out of Italy (OR 1.55 vs. 3.63). As much as 9 studies 
published after 2008 could not find differences between SEQ and STT whereas almost all Italian 
studies (but one) performed in 2007 and before showed that patients receiving SEQ could benefit 
more than those receiving STT.  
[17]
Also, another theory advocated higher STT cure rates within early studies due to investigators 
involving initially more patients with peptic ulcers, in which eradication rates were reported better 
than in patients with NUD.
 Published literature on the topic argues antibiotic resistance might be one of the 
most relevant factors mediating therapies’ efficacy trend through the years. 
[90] This statement could be potentially extended in the same way to 
justify SEQ eradication trends. However, data from present meta-analysis indicated that SEQ was 
less influenced by the type of the disease (PUD vs. NUD) than STT did. 
Confounding variables 
It is worth noting that from the results of this meta-analysis, it was not possible to determine the 
reason why studies published before 2008 resulted in higher treatment efficacy following SEQ (92%) 
compared with those published after 2008 (80%).  The cause could depend on the modulating effect 
of either the geographic region or the publication date of the included studies. 
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As mentioned, only Italian studies were published before year 2008 and treatment success or failure 
only relied on these studies. Additionally, no study was reported to be published in year 2009, which 
added a cut-off point to the time trend-line making it challenging to interpret. 
In order to investigate how these studies’ characteristics might be associated with the intervention 
effects, meta-regression was considered as an extension to subgroup analyses as it allows the effects 
of multiple factors (geographic region and publication date) to be investigated simultaneously. 
 However, it was finally decided not to perform the aforementioned analysis. As per the 
recommendation in The Cochrane Handbook of Interventions,[33]
Dyspepsia (functional or non-investigated) is a common condition, and no therapy has been yet 
described in treating effectively this disorder. Yet before SEQ was postulated, several investigations 
attempted to identify the relationship between H. pylori and NUD and whether eradication of the 
infection produced relief of dyspeptic symptoms in patients with NUD. The majority of the studies 
yielded with poor or inconclusive results.
 meta-regression should not be 
considered when there are fewer than 10 studies in a meta-analysis.  In our case, 11 and 9 studies 
respectively were pooled in each of the subgroup analyses.  
Medical condition 
[91, 92]
As reported in previous studies,
  
Findings of the current meta-analysis suggest that eradication rates following SEQ were equal in 
NUD and PUD patients (86%). However, when both of the 2 therapies were compared, SEQ was 
statistically more effective than STT among patients with PUD, whereas differences between the 2 
regimens could not be demonstrated among patients with NUD, probably due to the fact that STT 
obtains higher eradication rates in PUD than in NUD, which would reduce the difference with SEQ in 
those patients. 
[29, 50]
In order to support and reinforce the curative effect of STT some studies did focus on investigating 
treatment durations. It has been postulated that longer regimens, for example extending STT to 14 
days might result in higher cure rates.
 the fact that eradication rates in both PUD and NUD patients 
following SEQ were similar suggests that the sequential scheme might overcome differences of 
patients´ baseline medical conditions in a similar manner, or that the underlying disease itself is not 
a moderator neither a predictor of the treatment outcome. 
STT length 
[93-96] 
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In the current meta-analysis no differences in terms of efficacy between SEQ and STT regimens were 
found when STT lasted 14 days. Given these results, the final decision regarding the administration 
of one or the other will depend on the safety and cost-effectiveness of both therapies in each 
context.  
PPI type 
Eradication rates with SEQ were higher than with STT in patients using both new generation and old 
generation PPIs. Findings of the current meta-analysis in SEQ treatment appeared to show an 
increase in efficacy with new generation PPIs when compared to old generation PPIs as described for 
STT in former meta-analyses.[97] 98[ ]
Concerning dosage, almost all studies but 2 used the different PPIs at standard doses. One study
 
Moreover, within the subgroup analysis, the difference in efficacy between therapies was even 
greater when using new generation PPIs. 
[54]
Unfortunately, no further assessment regarding dosage could be performed given no more of the 
included studies used high-dose PPIs. Nonetheless former meta-analyses did already advocate the 
clear benefit of high-dose PPIs compared to standard-dose for treatment of H. pylori infection with 7 
days STT.
 
used esomeprazole 40 mg twice daily. H. pylori cure rate was reported greater with SEQ than with 
STT (95% vs. 75%, respectively) and was among the highest eradication rates (95%) achieved with 
SEQ across the included studies.  
[99]
Antimicrobial resistance has been considered the main responsible factor for the low efficacy of 
standard triple therapies and for the decrease in eradication rates with SEQ.
 
Antibiotic resistance 
Antibiotic resistance was scarcely reported: only 5 studies reported clarithromycin, and 4 reported 
nitroimidazole resistances. This represented a major limitation of current systematic review due to 
the lack of reporting of reliable, consistent and updated information regarding the prevalence of 
antibiotic susceptibility and resistance within the primary included RCTs. However, although none of 
the subgroups showed significant differences between the two treatment arms, the results indicated 
that particularly patients with single clarithromycin resistance could benefit more from SEQ than 
from STT.  
[100-102] In the current 
meta-analysis, 3 studies published in Italy by Zullo et al, Vaira et al and Gatta et al in 2003, 2007 and 
2011 respectively showed that SEQ was significantly more beneficial than STT mainly in those 
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patients with bacterial resistance to clarithromycin. However, our meta-analysis has not been able 
to demonstrate such good efficacy figures for these patients.  
Moreover, the difference between SEQ and STT did not reach statistical significance in patients with 
clarithromycin resistant strains although the difference in eradication rates between SEQ and STT in 
the current meta-analysis (30%) was reported similar to the difference in eradication rates between 
SEQ and STT in two previous meta-analyses (57% and 37% respectively) published in 2008 by Jafri et 
al[77] and in 2009 by Gatta et al. 30[ ]
Previous data from meta-analysis showed similar results,
 Such differences between treatments could be due to a small 
sample size.  
Age of the population 
Only 3 RCTs assessed SEQ vs. STT in children. Treatment with SEQ was found more beneficial than 
with STT (85% vs. 71%) and similar to the adult population (84% vs. 74%, respectively). 
[30, 79]
Findings from the present review support data from previous meta-analyses,
 although as it was the case for adult 
patients, eradication rates with SEQ did not achieved the desired level of success. 
Safety 
Safety was assessed through the incidence of AEs of included studies. The main category reported 
was gastrointestinal distress such as abdominal pain, diarrhoea, nausea, glossitis and vomiting.  
From the studies addressing tolerance and compliance, the overall incidence of AEs with SEQ and 
STT was reported equal (18.5% in both arms). The interruption of treatment due to AEs was also 
similar between treatment arms (near 1% with SEQ and 1.5% with STT).  
[30, 31, 77]
For the meta-analysis purposes, ITT rates were reported as per primary author´s statements. That is, 
all patients after randomization were accounted for analysis and any clinical trial´s complications 
such as non-compliance, withdrawals, protocol deviations and anything happening after 
randomization where not considered.
 where AEs as 
well as compliance rates were found comparable between both regimens.  
Quality of the methodology of included studies: limitations and advantages 
Intention-to-treat reporting 
[103]
In the present meta-analysis, complete outcome data were available in all included studies but 2 
demanding situations were noted when collecting ‘figures’. First, in some studies the number of 
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patients randomized to each of the treatment arms was not provided,[66, 73]
 Furthermore, unmasked studies give a better estimation of the efficacy in clinical practice as it could 
be speculated that the more complex sequential regimen may affect compliance and therefore 
treatment success.
 therefore the ratio 
specifying the number of patients cured over the total number of patients randomized to the 
specific treatment arm had to be estimated from the provided percentage of patients cured. 
Estimated figures were not always exactly matching provided percentages. 
Secondarily, it was also noted that although ITT rates were used as per definition above, from the 
perspective of the systematic review this could not be confirmed in most of the cases. The reason is 
that RCTs did not report reliable, complete and uniform definitions regarding participation rates 
within the study flow diagram. And thus, proportions of patients allocated to one treatment arm or 
another might be responding to different participation definitions. On the other hand, authors of 
primary studies might be reporting proportions without explicitly specifying to which participation 
definition they were initially referring.   
Reporting of baseline characteristics by treatment arm vs. not reporting findings by treatment arm 
Three studies assessed the efficacy of SEQ versus STT in both NUD and PUD patients without 
reporting results independently whereas NUD and PUD patients were assessed independently in 
eight studies each. Data from these 3 studies could not be included in the subgroup meta-analysis. 
Authors were contacted but these results were not provided. 
Masking of personnel and participants 
In this systematic review, most of the studies were not blinded (neither single nor double-blinded) 
and this could be considered as reducing considerably the quality of the included studies. However, 
it is generally accepted that H. pylori eradication is not affected by blindness as it is unlikely that the 
placebo effect would have an effect on the tests performed to confirm eradication nor in the 
bacteria itself. 
[104]
In the meta-analytic context, larger sample sizes are better to increase the confidence of an 
estimate. In this meta-analysis, as much as 13 studies (46%) had a sample size of less than 100 
patients at randomization. Post-hoc sensitivity analyses did not show to improve the overall effect 
size of SEQ when sample sizes of these same studies were doubled in each of the arms. This 
conferred robustness to the results of the meta-analysis.  
 
Sample size 
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Recommendations, other treatments for H. pylori eradication and further research 
At present STT is recommended as first line therapy for the eradication of H. pylori in several 
countries.[2]
STT can easily be converted into a non-bismuth quadruple therapy (either sequentially or 
concomitantly). Recently, a review evaluated findings of previous RCTs that had compared non-
bismuth quadruple therapies with STT. Results showed that concomitant therapy is equally well 
tolerated than STT but still more effective.
 On the other hand, many studies have confirmed a better efficacy of SEQ especially 
when compared to 7 and 10 days STT. As previously mentioned, SEQ also reported encouraging 
results when used among clarithromycin-resistant populations.  
[105] Further to this research, an additional meta-analysis of 
RCTs comparing the concomitant and the standard triple therapy demonstrated non-bismuth 
quadruple (concomitant) therapy appeared to be an effective, safe, and well-tolerated alternative to 
STT and was reported less complex than SEQ. 106[ ]
However, there is a renewed need to update findings of the aforementioned meta-analysis. More 
recent studies have evaluated the use of non-bismuth quadruple therapies (both sequential and 
concomitant regimens) in clinical settings with increased clarithromycin resistance rates and 
although differences did not reach statistical significance, there was a tendency towards better 
efficacy with concomitant therapy.
 
[107-110] 
As per findings of the current meta-analysis, it is clear that, overall, SEQ is a better strategy than STT 
in the majority of the settings assessed. However, further robust assessment should focus on 
investigating the definitive better efficacy of SEQ when compared with STT lasting 14 days.  
In any case, the overall efficacy obtained with SEQ treatment in the meta-analysis was sub-optimal. 
Moreover, there was a trend towards a reduction of efficacy in SEQ over the years which does not 
generate good future perspectives for this strategy. 
Further research would be also essential comparing non-bismuth quadruple therapies (concomitant) 
with SEQ, so that a clear recommendation could be made towards a generalized change in first-line 
H. pylori treatment.  
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6. Authors’ conclusions 
The present systematic review and meta-analysis provided further and robust assessment across a 
much broader range of patients comparing SEQ versus STT than in previously published reviews.  
Findings showed a clear benefit of SEQ over STT (7 and 10 days) in treatment naïve H. pylori infected 
patients. It was also confirmed the higher efficacy of SEQ vs. STT among patients with clarithromycin 
bacterial resistance. 
However, as it is clearly demonstrated that STT efficacy is sub-optimal, a generalized change in first 
line treatment needs to be considered especially in those settings where eradication rates with STT 
have been reported lower. 
Given the results of the present meta-analysis, whether SEQ should be the substitute of choice will 
depend on specific characteristics of the regional context, and, more importantly, the efficacy 
obtained with other proposed treatments such as non-bismuth quadruple concomitant regimen. 
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7. Conclusiones 
La presente revisión sistemática y metaanálisis proporciona una evaluación más exhaustiva de la 
eficacia de la terapia secuencial frente a la triple terapia clásica en comparación con las revisiones 
publicadas anteriormente. Se ha incluido un número mayor de pacientes, actualizando los resultados 
previos y confiriendo mayor evidencia científica a dichos resultados. 
El metaanálisis ha demostrado que la terapia secuencial es más efectiva que la triple terapia clásica 
(durante 7 ó 10 días) en el tratamiento de primera línea en pacientes infectados por H. pylori. Esta 
mayor eficacia no se evidenció, sin embargo, cuando la triple terapia se administraba durante 14 
días. 
También se ha confirmado el mayor beneficio de la terapia secuencial frente a la triple clásica entre 
aquellos pacientes con resistencia bacteriana a la claritromicina. 
Sin embargo, también se ha puesto de manifiesto que la tasa de erradicación con la terapia 
secuencial es claramente subóptima y decreciente con el tiempo.  
Según los resultados del presente meta-análisis, la cuestión sobre si la terapia secuencial debe 
sustituir a la triple terapia clásica como tratamiento de elección de primera línea para la infección de 
H. pylori dependerá de las características específicas en cada ámbito regional y, sobre todo, de la 
eficacia obtenida con otros tratamientos erradicadores como la terapia cuádruple concomitante. 
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8. Appendix: search strategy (electronic databases) 
Ovid MEDLINE(R): searched from 1948 to May 2013 
1. randomized controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomized.ab. 
4. placebo.ab. 
5. clinical trials as topic.sh. 
6. randomly.ab. 
7. trial.ti. 
8. or/1-7 
9. exp animals/ not humans.sh. 
10. 8 not 9 
11. Helicobacter pylori/ 
12. (H adj3 pylori).mp. [mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, unique identifier] 
13. (helicobacter adj3 pylori).mp. [mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, subject heading word, unique 
identifier] 
14. (C adj3 pylori).mp. [mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, unique identifier] 
15. Campylobacter.mp. [mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, unique identifier] 
16. Helicobacter Infections/ 
17. or/11-16 
18. ((triple or standard) adj2 (regimen or therapy or treatment)).tw. 
19. (sequential adj2 (regimen or therapy or treatment)).tw. 
20. PPI.mp. 
21. Proton Pump Inhibitors/ 
22. (Clarithromycin or biaxin or Claripen or Claridar or clarith or Crixan or Clacid or Fromilid or infex 
or klaricid or Klabax or Klacid or Vikrol).mp. 
23. (amoxicillin or amoxycillin or actimoxi or almodan or amix or amox or amopen or amoram or 
amoxicot or amoxil or amrit or biomox or clamoxyl or dispermox or galenamox or larotid or moxatag 
or moxilin or p-hydroxyampicillin or penamox or polymox or respillin or rimoxallin or senox or sumox 
or Tormoxin or trimox or utimox or wymox or zoxycil).mp. 
24. (Alphamox or Amocla or Amoksibos or Amoxiclav Sandoz or Amoxidal or Amoxin or Amoksiklav 
or Amoxibiotic or Amoxicilina or Apo-Amoxi or Augmentin or Bactox or Betalaktam or Cilamox or 
Curam or Dedoxil or Duomox or E-Mox or Enhancin or Gimalxina or Geramox or Hiconcil or Isimoxin 
or Klavox or Lamoxy or Moxilen or Moxypen or Moxyvit or Nobactam or Novamoxin or Ospamox or 
Panklav or Pamoxicillin or Panamox or Samthongcillin or Sinacilin or Tolodina or Yucla or Zerrsox or 
Zimox).mp. 
25. nitroimidazoles/ or metronidazole/ or tinidazole/ 
26. nitroimidazole*.tw. 
27. (Metronidazole or nabact or clont or danizol or edg dentalgel or elyzol or flagyl or gineflavir or 
metrocream or metrodzhil or metrogel or metrolotion or metrolyl or metronizole or metrotop or 
metrovex or metrozol or metryl or noritate or norzol or nydamax or obagi or protostat or rozex or 
satric or trichopol or tricom or trivazol or vandazole or vitazol or zadstat or zidoval).mp. 
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28. (Tinidazole or bioshik or fasigin or fasigyn* or tindamax or tricolam).mp. 
29. or/18-28 
30. 17 and 29 
31. 10 and 30 
 
EBM Reviews - Cochrane Central Register of Controlled Trials searched on 4th Quarter 2013  
1. Helicobacter pylori/   
2. pylori.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] 
3. Helicobacter Infections/   
4. or/1-3     
5. ((triple or standard) adj2 (regimen or therapy or treatment)).tw. 
6. (sequential adj2 (regimen or therapy or treatment)).tw. 
7. PPI.mp.    
8. Proton Pump Inhibitors/   
9. (Clarithromycin or biaxin or Claripen or Claridar or clarith or Crixan or Clacid or Fromilid or infex or 
klaricid or Klabax or Klacid or Vikrol).mp. 
10. (amoxicillin or amoxycillin or actimoxi or almodan or amix or amox or amopen or amoram or 
amoxicot or amoxil or amrit or biomox or clamoxyl or dispermox or galenamox or larotid or moxatag 
or moxilin or p-hydroxyampicillin or penamox or polymox or respillin or rimoxallin or senox or sumox 
or Tormoxin or trimox or utimox or wymox or zoxycil).mp. 
11. (Alphamox or Amocla or Amoksibos or Amoxiclav Sandoz or Amoxidal or Amoxin or Amoksiklav 
or Amoxibiotic or Amoxicilina or Apo-Amoxi or Augmentin or Bactox or Betalaktam or Cilamox or 
Curam or Dedoxil or Duomox or E-Mox or Enhancin or Gimalxina or Geramox or Hiconcil or Isimoxin 
or Klavox or Lamoxy or Moxilen or Moxypen or Moxyvit or Nobactam or Novamoxin or Ospamox or 
Panklav or Pamoxicillin or Panamox or Samthongcillin or Sinacilin or Tolodina or Yucla or Zerrsox or 
Zimox).mp. 
12. nitroimidazoles/ or metronidazole/ or tinidazole/ 
13. nitroimidazole*.tw.   
14. (Metronidazole or nabact or clont or danizol or edg dentalgel or elyzol or flagyl or gineflavir or 
metrocream or metrodzhil or metrogel or metrolotion or metrolyl or metronizole or metrotop or 
metrovex or metrozol or metryl or noritate or norzol or nydamax or obagi or protostat or rozex or 
satric or trichopol or tricom or trivazol or vandazole or vitazol or zadstat or zidoval).mp. 
15. (Tinidazole or bioshik or fasigin or fasigyn* or tindamax or tricolam).tw. 
16. or/5-15    
17. 4 and 16    
 
CINAHL: searched up to May, 2013 
S12   (S1 and S11)     
S11   S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10   
S10   Tinidazole     
S9   Metronidazole     
S8   nitroimidazole*     
S7   amoxicillin     
S6   Clarithromycin     
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S5   Proton Pump Inhibitors    
S4   PPI      
S3   sequential and ( (regimen or therapy or treatment) )  
S2   ( (triple or standard) ) and ( (regimen or therapy or treatment) )   
S1   Helicobacter pylori    
  
EMBASE: searched from 1980 to May 2013  
1. Clinical trial/ 
2. Randomized controlled trial/ 
3. Randomization/ 
4. Single-Blind Method/ 
5. Double-Blind Method/ 
6. Cross-Over Studies/ 
7. Random Allocation/ 
8. Placebo/ 
9. Randomi?ed controlled trial$.tw. 
10. Rct.tw. 
11. Random allocation.tw. 
12. Randomly allocated.tw. 
13. Allocated randomly.tw. 
14. (allocated adj2 random).tw. 
15. Single blind$.tw. 
16. Double blind$.tw. 
17. ((treble or triple) adj blind$).tw. 
18. Placebo$.tw. 
19. Prospective study/ 
20. or/1-19 
21. Case study/ 
22. Case report.tw. 
23. Abstract report/ or letter/ 
24. or/21-23 
25. 20 not 24 
26. Helicobacter pylori/ 
27. pylori.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer] 
28. Helicobacter Infections/ 
29. or/26-28 
30. ((triple or standard) adj2 (regimen or therapy or treatment)).tw. 
31. (sequential adj2 (regimen or therapy or treatment)).tw. 
32. PPI.mp. 
33. Proton Pump Inhibitors/ 
34. (Clarithromycin or biaxin or Claripen or Claridar or clarith or Crixan or Clacid or Fromilid or infex 
or klaricid or Klabax or Klacid or Vikrol).mp. 
35. (amoxicillin or amoxycillin or actimoxi or almodan or amix or amox or amopen or amoram or 
amoxicot or amoxil or amrit or biomox or clamoxyl or dispermox or galenamox or larotid or moxatag 
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or moxilin or p-hydroxyampicillin or penamox or polymox or respillin or rimoxallin or senox or sumox 
or Tormoxin or trimox or utimox or wymox or zoxycil).mp. 
36. (Alphamox or Amocla or Amoksibos or Amoxiclav Sandoz or Amoxidal or Amoxin or Amoksiklav 
or Amoxibiotic or Amoxicilina or Apo-Amoxi or Augmentin or Bactox or Betalaktam or Cilamox or 
Curam or Dedoxil or Duomox or E-Mox or Enhancin or Gimalxina or Geramox or Hiconcil or Isimoxin 
or Klavox or Lamoxy or Moxilen or Moxypen or Moxyvit or Nobactam or Novamoxin or Ospamox or 
Panklav or Pamoxicillin or Panamox or Samthongcillin or Sinacilin or Tolodina or Yucla or Zerrsox or 
Zimox).mp. 
37. nitroimidazoles/ or metronidazole/ or tinidazole/ 
38. nitroimidazole*.tw. 
39. (Metronidazole or nabact or clont or danizol or edg dentalgel or elyzol or flagyl or gineflavir or 
metrocream or metrodzhil or metrogel or metrolotion or metrolyl or metronizole or metrotop or 
metrovex or metrozol or metryl or noritate or norzol or nydamax or obagi or protostat or rozex or 
satric or trichopol or tricom or trivazol or vandazole or vitazol or zadstat or zidoval).mp. 
40. (Tinidazole or bioshik or fasigin or fasigyn* or tindamax or tricolam).tw. 
41. or/30-40 
42. 29 and 41 
43. 25 and 42 
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